Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment

F S Van Dijk, D O Sillence, F S Van Dijk, D O Sillence

Abstract

Recently, the genetic heterogeneity in osteogenesis imperfecta (OI), proposed in 1979 by Sillence et al., has been confirmed with molecular genetic studies. At present, 17 genetic causes of OI and closely related disorders have been identified and it is expected that more will follow. Unlike most reviews that have been published in the last decade on the genetic causes and biochemical processes leading to OI, this review focuses on the clinical classification of OI and elaborates on the newly proposed OI classification from 2010, which returned to a descriptive and numerical grouping of five OI syndromic groups. The new OI nomenclature and the pre-and postnatal severity assessment introduced in this review, emphasize the importance of phenotyping in order to diagnose, classify, and assess severity of OI. This will provide patients and their families with insight into the probable course of the disorder and it will allow physicians to evaluate the effect of therapy. A careful clinical description in combination with knowledge of the specific molecular genetic cause is the starting point for development and assessment of therapy in patients with heritable disorders including OI. © 2014 The Authors. American Journal of Medical Genetics Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Keywords: classification; collagen type I; fractures; heterogeneity; osteogenesis imperfecta.

© 2014 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Overview of collagen type I biosynthesis. Collagen type I consists of two α1-chains and one α2-chain. After translation, pro-α1-chains and pro-α2 chains are processed in the rough Endoplasmic reticulum (rER). These chains have to align in order to start the folding process of (pro)collagen type I into a triple helix. The next step is alignment of the three chains in order to commence folding into a triple helical structure. During this folding process, post-translational modification by specific proteins takes place. The genes encoding proteins involved in post-translational modification and in which mutations have been reported to cause OI, are depicted in this figure. After transport of procollagen type I to the Golgi complex and following exocytosis into the extracellular matrix, cleavage of the C-and N-propeptides results in formation of collagen type I. Subsequently, cross-linking of collagen type I molecules leads to formation of fibrils. Multiple collagen type I fibrils form into collagen fibers, important constituents of bone.

References

    1. Alcausin MB, Ault J, Briody J, Pacey V, Mcquade M, Bridge C, Engelbert RHH, Sillence DO, Munns CF. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. Horm Res Paediatr. 2013;79:333–340.
    1. Astrom E, Jorulf H, Soderhall S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child. 2007;92:332–338.
    1. Bailleul-Forestier I, Berdal A, Vinchier F, de Ravel T, Fryns JP, Verloes A. The genetic basis of inherited anomalies of the teeth. Part 2: syndromes with significant dental development. EJMG. 2008;51:383–408.
    1. Baljet B. Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome) Ann Anat. 2002;184:1–7.
    1. Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006;355:2757–2764.
    1. Battle WH, Shattock SG. A remarkable case of diffuse cancellous osteoma of the femur, following a fracture, in which similar growths afterwards developed in connection with other bones. Proc R Soc Med. 1908;1:83–115.
    1. Bauze RV, Smith R, Francis MJO. A new look at osteogenesis imperfecta. A clinical, radiological and biochemical study of forty-two patients. J Bone Joint Surg. 1975;57B:2.
    1. Berfenstam R, Smars G. Osteogenesis imperfecta: A survey with some results from an introductory study of the incidence of the disease in Sweden. Sven Lakartidn. 1956;53:2113–2123.
    1. Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, Devogelaer J, Hangartner T, Hosszú E, Lane JM, Lorenc R, Mäkitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD. Risedronate in children with osteogenesis imperfecta: A randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424–1432.
    1. Byers P, Cole W. Osteogenesis imperfecta. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders. New York, NY: Wiley-Liss; 2002. pp. 385–430.
    1. Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet. 2012;46:475–497.
    1. Cabral WA, Barnes AM, Adeyemo A, Cushing K, Chitayat D, Porter FD, Panny SR, Gulamali-Majid F, Tishkoff SA, Rebbeck TR, Gueye SM, Bailey-Wilson JE, Brody LC, Rotimi CN, Marini JC. A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta. Genet Med. 2012;14:543–551.
    1. Caniggia A, Stuart C, Guideri R. Fragilitas ossium hereditaria tarda: Ekman-Lobstein disease. Acta Med Scand Suppl. 1958;340:1–172.
    1. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012;91:343–348.
    1. Cho TJ, Moffat P. Osteogenesis imperfecta type V. In: Shapiro J, Byers P, Glorieux F, Sponseller P, editors. Osteogenesis imperfecta: A translational approach to brittle bone disease. 1st edition. London, UK: Academic Press; 2014.
    1. Chu ML, Williams CJ, Pepe G, Hirsch JL, Prockop DJ, Ramirez F. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983;304:78–80.
    1. Dalgleish R. The human type I collagen mutation database. Nucleic Acids Res. 1997;25:181–187.
    1. Dalgleish R. The human collagen mutation database 1998. Nucleic Acids Res. 1998;26:253–255.
    1. DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. 2004;35:1038–1045.
    1. Eichholtz W, Muller D. Electron microscopy findings on the cornea and sclera in osteogenesis imperfecta. Klin Monbl Augenheilkd. 1972;161:646–653.
    1. Emery SC, Karpinski NC, Hansen L, Masliah E. Abnormalities in central nervous system development in osteogenesis imperfecta type II. Pediatr Dev Pathol. 1999;2:124–130.
    1. Fahiminiya S, Majewski J, Mort M, Mofatt P, Glorieux FH, Rauch F. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet. 2013;50:345–348.
    1. Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B, Abrahamsen B, Brixen K. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res. 2012;27:1405–1412.
    1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7:540–557.
    1. Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga V, Rossini M, Adami S. The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. J Clin Densitom. 2003;6:173–177.
    1. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–952.
    1. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ. Type V osteogenesis imperfecta: A new form of brittle bone disease. J Bone Miner Res. 2000;15:1650–1658.
    1. Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011;29:279–290.
    1. Hartikka H, Mäkitie O, Männikkö M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, Sochett EB. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res. 2005;20:783–789.
    1. Holcomb DY. A fragile boned family. J Hered. 1931;22:105.
    1. Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, Fischer B, Yigit G, Janda CY, Becker J, Breer S, Altunoglu U, Grünhagen J, Krawitz P, Hecht J, Schinke T, Makareeva E, Lausch E, Cankaya T, Caparrós-Martín JA, Lapunzina P, Temtamy S, Aglan M, Zabel B, Eysel P, Koerber F, Leikin S, Garcia KC, Netzer C, Schönau E, Ruiz-Perez VL, Mundlos S, Amling M, Kornak U, Marini J, Wollnik B. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet. 2013;92:565–574.
    1. Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: A nationwide survey. Ann Otol Rhinol Laryngol. 2002;111:939–946.
    1. Kuurila K, Kentala E, Karjalainen S, Pynnönen S, Kovero O, Kaitila I, Grénman R, Waltimo J. Vestibular dysfunction in adult patients with osteogenesis imperfecta. Am J Med Genet Part A. 2003;120A:350–358.
    1. Laine CM, Joeng KS, Campeau PS, Kiuranta R, Tarkkonen K, Grover M, Lu JT, Pekkinen M, Wessman M, Heino TJ, Nierminen-Pihala V, Aronen M, Laine T, Kröger H, Cole WG, Lehesjoki A, Nevarez L, Krakow D, Curry CJR, Cohn DH, Gibbs RA, Lee BH, Mäkitie O. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med. 2013;368:1809–1847.
    1. Lu PW, Briody JN, Ogle GD, Morley K, Humphries IR, Allen J, Howman-Giles R, Sillence D, Cowell CT. Bone mineral density of total body, spine, and femoral neck in children and young adults: A cross-sectional and longitudinal study. J Bone Miner Res. 1994;9:1451–1458.
    1. Martínez-Glez V, Valencia M, Caparrós-Martín JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D, Giunta C, Lapunzina P, Ruiz-Perez VL. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat. 2012;33:343–350.
    1. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res. 2005;20:1235–1243.
    1. Munns CR, Sillence D. Osteogenesis imperfecta (and other disorders of bone matrix) In: Rimoin DL, Pyeritz PE, Korf BR, editors. Emery and Rimoin's principles and practice of medical genetics. Oxford, UK: Academic Press; 2013.
    1. Paterson CR, McAllion S, Miller R. Heterogeneity of osteogenesis imperfecta type I. J Med Genet. 1983;20:203–205.
    1. Peltier LF. The classic: Congenital osteomalacia. Olaus Jacob Ekman. Clin Orthop Relat Res. 1981:3–5.
    1. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846–1850.
    1. Puig-Hervás MT, Temtamy S, Aglan M, Valencia M, Martínez-Glez V, Ballesta-Martínez MJ, López-González V, Ashour AM, Amr K, Pulido V, Guillén-Navarro E, Lapunzina P, Caparrós-Martín JA, Ruiz-Perez VL. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome—osteogenesis imperfecta phenotypic spectrum. Hum Mutat. 2012;33:1444–1449.
    1. Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz DF, Dineen R, Harris C, Burton BK, Angle B, Kim K, Sussman MD, Weis M, Eyre DR, Russell DW, McCarthy KJ, Steiner RD, Byers PH. Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet. 2011;20:1595–1609.
    1. Pyott SM, Tran TT, Leistritz DF, Pepin MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet. 2013;92:590–597.
    1. Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J. 2011;161:523–529.
    1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377–1385.
    1. Schwarze U, Cundy T, Pyott SM, Christiansen HE, Hegde MR, Bank RA, Pals G, Ankala A, Conneely K, Seaver L, Yandow SM, Raney E, Babovic-Vuksanovic D, Stoler J, Ben-Neriah Z, Segel R, Lieberman S, Siderius L, Al-Aqeel A, Hannibal M, Hudgins L, McPherson E, Clemens M, Sussman MD, Steiner RD, Mahan J, Smith R, Anyane-Yeboa K, Wynn J, Chong K, Uster T, Aftimos S, Sutton VR, Davis EC, Kim LS, Weis MA, Eyre D, Byers PH. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Hum Mol Genet. 2013;22:1–17.
    1. Seedorf KS. Osteogenesis imperfecta. A study of clinical features and heredity based on 55 Danish families comprising 18 affected members. Copenhagen, Denmark: Universitetsforlaget Aarhus; 1949.
    1. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, Iden S, Wirth B, Eysel P, Koerber F, Schoenau E, Bohlander SK, Wollnik B, Netzer C. A mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 2012;91:349–357.
    1. Shaheen R, Alazami AM, Alshammari MJ, Faqeih E, Alhashmi N, Mousa N, Alsinani A, Ansari S, Alzahrani F, Al-Owain M, Alzayed ZS, Alkuraya FS. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet. 2012;49:630–635.
    1. Sillence DO. Bone dysplasia. Genetic and ultrastructural aspects with reference to osteogenesis imperfecta. Ann Arbor, Michigan: University Microfilms; 1980.
    1. Sillence DO. Craniocervical abnormalities in osteogenesis imperfecta: Genetic and molecular correlation. Pediatr Radiol. 1994;24:427–430.
    1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–116.
    1. Sillence DO, Barlow KK, Garber AP, Hall JG, Rimoin DL. Osteogenesis imperfecta type II delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet. 1984;17:407–423.
    1. Sillence DO, Barlow KK, Cole WG, Dietrich S, Garber AP, Rimoin DL. Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet. 1986;23:821–832.
    1. Sillence DO, Butler B, Latham M, Barlow K. Natural history of blue sclerae in osteogenesis imperfecta. Am J Med Genet. 1993;45:183–186.
    1. Smars G. Osteogenesis imperfecta in Sweden. Clinical, genetic, epidemiological and socio-medical aspects. Stockholm, Sweden: Scandinavian University Books; 1961.
    1. Spranger J. Invited editorial comment: Osteogenesis imperfecta: A pasture for splitters and lumpers. Am J Med Genet. 1984;17:425–428.
    1. Spranger J, Brill P, Poznanski A. Bone dysplasias. An atlas of genetic disorders of skeletal development. Oxford, UK: Oxford University Press; 2003.
    1. Steiner RD, Adsit J, Basel D. COL1A1/2-Related Osteogenesis Imperfecta. Genereviews. 2013 [ ]
    1. Swinnen FK, Coucke PJ, De Paepe AM, Symoens S, Malfait F, Gentile FV, Sangiorgi L, D'Eufemia P, Celli M, Garretsen TJ, Cremers CW, Dhooge IJ, De Leenheer EM. Osteogenesis imperfecta: The audiological phenotype lacks correlation with the genotype. Orphanet J Rare Dis. 2011;6:88.
    1. Symoens S, Malfait F, D Hondt S, Callewaert B, Dheedene A, Steyaert W, Bächinger HP, De Paepe A, Kayserili H, Coucke PJ. Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet J Rare Dis. 2013;8:154.
    1. van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, Symoens S, Sistermans EA, Pals G. EMQN Best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20:11–19.
    1. van Dijk FS, Cobben JM, Kariminejad A, Maugeri A, Nikkels PG, van Rijn RR, Pals G. Osteogenesis imperfecta: A review with clinical examples. Mol Syndromol. 2011;2:1–20.
    1. van Dijk FS, Pals G, van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1–5.
    1. van Dijk FS, Zillikens MC, Micha D, Riessland M, Marcelis CLM, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, Pruijs HE, Rubio-Gozalbo ME, Zwertbroek R, Moutaouakil Y, Egthuijsen J, Hammerschmidt M, Bijman R, Semeins CM, Bakker AD, Everts V, Klein-Nulend J, Campos-Obando N, Hofman A, te Meerman GF, Verkerk AJMH, Uitterlinden AG, Maugeri A, Sistermans EA, Waisfisz Q, Meijers-Heijboer H, Wirth B, Simon MEH, Pals G. PLS3 mutations in X-linked osteoporosis and fractures. N Eng J Med. 2013;369:1529–1536. Accepted for publication in.
    1. Volodarsky M, Markus B, Cohen I, Staretz-Chacham O, Flusser H, Landau D, Shelef I, Langer Y, Birk OS. A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta. Hum Mutat. 2013;34:582–586.
    1. Wallis GA, Sykes B, Byers PH, Mathew CG, Viljoen D, Beighton P. Osteogenesis imperfecta type III: Mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. J Med Genet. 1993;30:492–496.
    1. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet Part A. 2011;155A:943–968.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel